Literature DB >> 28698977

Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia.

Aritro Nath1, Jacqueline Wang2, R Stephanie Huang3.   

Abstract

The advent of targeted therapeutics has greatly improved outcomes of chronic myeloid leukemia (CML) patients. Despite increased efficacy and better clinical responses over cytotoxic chemotherapies, many patients receiving targeted drugs exhibit a poor initial response, develop drug resistance, or undergo relapse after initial success. This inter-individual variation in response has heightened the interest in studying pharmacogenetics and pharmacogenomics (PGx) of cancer drugs. In this review, we discuss the influence of various germline and somatic factors on targeted drug response in CML. Specifically, we examine the role of genetic variants in drug metabolism genes, i.e. CYP3A family genes, and drug transporters, i.e. ABC and SLC family genes. Additionally, we focus on acquired somatic variations in BCR-ABL1, and the potential role played by additional downstream signaling pathways, in conferring resistance to targeted drugs in CML. This review highlights the importance of PGx of targeted therapeutics and its potential application to improving treatment decisions and patient outcomes.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28698977      PMCID： PMC5693681          DOI： 10.1007/s40291-017-0292-x

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN： 1177-1062            Impact factor:   4.074


  112 in total

1.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

2.  Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.

Authors:  Simona Soverini; Sabrina Colarossi; Alessandra Gnani; Gianantonio Rosti; Fausto Castagnetti; Angela Poerio; Ilaria Iacobucci; Marilina Amabile; Elisabetta Abruzzese; Ester Orlandi; Franca Radaelli; Fabrizio Ciccone; Mario Tiribelli; Roberto di Lorenzo; Clementina Caracciolo; Barbara Izzo; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani; Giovanni Martinelli
Journal:  Clin Cancer Res       Date:  2006-12-15       Impact factor: 12.531

3.  Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice.

Authors:  Flavia da Cunha Vasconcelos; Marcos Antonio Mauricio Scheiner; Arthur Moellman-Coelho; André Luiz Mencalha; Ilana Zalcberg Renault; Vivian Mary Rumjanek; Raquel Ciuvalschi Maia
Journal:  Leuk Res       Date:  2016-10-12       Impact factor: 3.156

4.  Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.

Authors:  Yuji Yamakawa; Akinobu Hamada; Reiko Nakashima; Misato Yuki; Chie Hirayama; Tatsuya Kawaguchi; Hideyuki Saito
Journal:  Ther Drug Monit       Date:  2011-04       Impact factor: 3.681

5.  Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.

Authors:  Sabrina Angelini; Simona Soverini; Gloria Ravegnini; Matt Barnett; Eleonora Turrini; Mark Thornquist; Fabrizio Pane; Timothy P Hughes; Deborah L White; Jerald Radich; Dong Wook Kim; Giuseppe Saglio; Daniela Cilloni; Ilaria Iacobucci; Giovanni Perini; Richard Woodman; Giorgio Cantelli-Forti; Michele Baccarani; Patrizia Hrelia; Giovanni Martinelli
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

Review 6.  Chronic myeloid leukaemia.

Authors:  Jane F Apperley
Journal:  Lancet       Date:  2014-12-05       Impact factor: 79.321

7.  Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.

Authors:  Luciene Terezina de Lima; Douglas Vivona; Carolina Tosin Bueno; Rosario D C Hirata; Mario H Hirata; André D Luchessi; Fabíola Attié de Castro; Maria de Lourdes F Chauffaille; Maria A Zanichelli; Carlos S Chiattone; Vania T M Hungria; Elvira M Guerra-Shinohara
Journal:  Med Oncol       Date:  2014-01-29       Impact factor: 3.064

8.  Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.

Authors:  Simrit Parmar; Efstratios Katsoulidis; Amit Verma; Yongzhong Li; Antonella Sassano; Lakhvir Lal; Beata Majchrzak; Farhad Ravandi; Martin S Tallman; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2004-03-31       Impact factor: 5.157

9.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

10.  Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib.

Authors:  Géraldine Dessilly; Nadtha Panin; Laure Elens; Vincent Haufroid; Jean-Baptiste Demoulin
Journal:  Sci Rep       Date:  2016-07-12       Impact factor: 4.379
View more
  5 in total

1.  Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib.

Authors:  Federica Loscocco; Giuseppe Visani; Annamaria Ruzzo; Irene Bagaloni; Fabio Fuligni; Sara Galimberti; Antonello Di Paolo; Fabio Stagno; Patrizia Pregno; Mario Annunziata; Antonella Gozzini; Sara Barulli; Elisa Gabucci; Mauro Magnani; Alessandro Isidori
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

Review 2.  Pharmacogenetics of Drugs Used in the Treatment of Cancers.

Authors:  Beata Franczyk; Jacek Rysz; Anna Gluba-Brzózka
Journal:  Genes (Basel)       Date:  2022-02-07       Impact factor: 4.096

Review 3.  Leveraging Single-Cell Approaches in Cancer Precision Medicine.

Authors:  Aritro Nath; Andrea H Bild
Journal:  Trends Cancer       Date:  2021-02-06

Review 4.  Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients.

Authors:  Engin Ulukaya; Didem Karakas; Konstantinos Dimas
Journal:  Medicina (Kaunas)       Date:  2021-06-19       Impact factor: 2.430

5.  Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma.

Authors:  Fatemeh Aghai; Sebastian Zimmermann; Max Kurlbaum; Pius Jung; Theo Pelzer; Hartwig Klinker; Nora Isberner; Oliver Scherf-Clavel
Journal:  Anal Bioanal Chem       Date:  2020-11-06       Impact factor: 4.142
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.